Market Herald logo


Be the first with the news that moves the market
  • Cellmid (CDY) closes slightly higher following the release of its latest quarterly financial report
  • The company ends the quarter with just shy of $7 million cash in the bank, with this figure expected to grow to $8 million by the end of July
  • This is despite net cash outflows of $1.96 million for the quarter, which is steeper than both the March 2021 quarter and the June 2020 quarter
  • Cellmid’s Advangen business improved its net loss by 43 per cent over the 2021 financial year, despite a decline in annual revenue
  • Shares in Cellmid closed 1.69 per cent higher this afternoon at 6 cents each

Hair and skincare specialist Cellmid (CDY) closed slightly higher on the ASX today following the release of its latest quarterly financial report.

While the company’s net cash flow was negative by around $1.96 million for the June 2021 quarter, Cellmid had just shy of $7 million worth of cash in the bank at the end of June thanks to an April capital raise.

What’s more, this cash balance doesn’t reflect the record $1.3 million made from Cellmid’s participation in the Japanese Today’s Special Value (TSV) television shopping channel event.

When counting this extra cash, Cellmid said it expected to have around $8 million in the bank at the end of July. This would place it in a “strong position” to deliver on its revenue growth and profitability objectives for the 2022 financial year.

The $1.96 million cash outflow result is steeper than the $153,000 in cash outflows from the March 2021 quarter and the $1.7 million from the June 2020 quarter. However Cellmid said the higher spending was mostly due to increased payments for inventory.

The company spent $907,000 on inventory payments over the three months to the end of June — 74 per cent higher than the same time last year. Cellmid said the increase spend was for the supply of products under a key Chinese distribution deal and for products sold at the Japanese TSV event.

Full-year health and beauty tech results

Cellmid is yet to release its audited 2021 financial year annual report, but the company said today its health and beauty tech business, Advangen, improved over the year.

Advangen’s annual loss was cut by 43 per cent to $1.33 million for the year compared to the $2.3 million loss last financial year.

This comes despite a fall in Advangen annual revenue, which dipped 18 per cent to $6.04 million for the year.

Cellmid said 7 per cent of this revenue drop could be attributed to changes in exchange rates, while ongoing COVID-19 restrictions had impacted the company’s most significant brick-and-mortar partners from before the pandemic.

Nevertheless, Cellmid said it had evolved the Advangen business over the past 12 months to have an increased focus on “direct to consumer” ecommerce channels and capitalise on growth potential in China.

With improved financial resources leading to new product development, Cellmid said it had formulated several new products to address growing market needs over the past year, with plans to launch some of these products in coming months.

Shares in Cellmid closed 1.69 per cent higher this afternoon at 6 cents each. The company has a $11 million market cap.

CDY by the numbers
More From The Market Herald

" Alterity Therapeutics (ASX:ATH) expands clinical development program

Alterity Therapeutics (ATH) is expanding the phase two clinical development program for its lead asset ATH434 in patients with Multiple System Atrophy (MSA).
Althea Group (ASX:AGH) - CEO, Joshua Fegan

" Althea Group (ASX:AGH) hits new high in sales receipts

Althea Group (AGH) brought in a new high of $4.5 million in customer receipts over the recently completed September quarter.
Singular Health Group (ASX:SHG) - Chief Operating Officer, James Hill

" Singular Health (ASX:SHG) collaborates with CSIRO and Osteopore (ASX:OSX)

Singular Health Group (SHG) will collaborate with CSIRO and Osteopore (OSX) for an artificial intelligence (AI) based tool to make patient-specific 3D cranial
ImpediMed (ASX:IPD) - MD and CEO, Richard Carreon

" ImpediMed (ASX:IPD) completes lymphoedema prevention trial

ImpediMed (IPD) has rounded off its PREVENT trial, successfully meeting its primary end point.